MarginsXMarginsX
Home › Markets › Health Care › ETRA

Electra Therapeutics Inc. (ETRA)

ETRA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$8.31
-6.00% on the day
Market cap
$522.4M
Small cap
Revenue
New registrant: no annual report filed under this company yet
Net income
New registrant: no annual report filed under this company yet

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerETRA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2026
SEC CIK0002088082
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials

New registrant: no annual report filed under this company yet.

Warning signs

Cash runway
not enough data
$256.4M cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$20.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$256.4M cash.Report 2026-09-30
Shares outstanding62,866,792 (2026-11-06).Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Mateo, California, United StatesPCAOB Form AP 2026-09-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $20.0M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$23.9MNot filed$256.4M$0Needs four quarters10-Q 2026-11-12
Q3 2026
2026-06-30
Not filed-$26.7MNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-11-12
Q3 2026
2026-03-31
Not filed-$22.2MNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-11-12
Q3 2026
2025-09-30
Not filed-$18.1MNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-11-12
Q3 2026
2025-06-30
Not filed-$17.6MNot filedNot filed$40.0MNeeds four quarters10-Q 2026-11-12
Q3 2026
2025-03-31
Not filed-$7.8MNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-11-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42026-09-18
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12

Source: SEC EDGAR submissions feed, 41 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+13.3%
1 month+2.7%
3 monthsNot enough price history
Year to dateNot enough price history
1 yearNot enough price history
From 52-week high-36.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
ENTXEntera Bio Ltd.$3.02-2.89%$525.9M
VALNValneva SE$5.65-0.18%$536.1M
DNAGinkgo Bioworks Holdings Inc.$8.50-11.55%$551.0M
IAMIambic Therapeutics Inc.$11.85-9.54%$561.7M
SANASana Biotechnology Inc.$1.88-6.93%$563.3M
RGNXREGENXBIO Inc.$7.32-4.19%$484.0M
CADLCandel Therapeutics Inc.$5.81-6.29%$455.8M
FENCFennec Pharmaceuticals Inc.$12.76+9.81%$450.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier